8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Feb 11, 2026·SEC
Neurocrine Biosciences, Inc.(NBIX)Earnings, Financials & Key Ratios
NBIX•NASDAQ
33.9× P/E·Price updated Jun 19, 2026
AboutNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.Show more
- Revenue$2.86B+21.4%
- EBITDA$649M+8.6%
- Net Income$479M+40.2%
- EPS (Diluted)4.67+41.9%
- Gross Margin98.18%-0.4%
- EBITDA Margin22.7%-10.6%
- Operating Margin21.64%-10.6%
- Net Margin16.73%+15.5%
- ROE16.38%+15.7%
NBIX Key Insights
Neurocrine Biosciences, Inc. (NBIX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 26.2% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 22.3%
- ✓Healthy 5Y average net margin of 12.5%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NBIX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NBIX Price & Volume
Neurocrine Biosciences, Inc. (NBIX) stock price & volume — 10-year historical chart
Loading chart...
NBIX Growth Metrics
Neurocrine Biosciences, Inc. (NBIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years64.45%
5 Years22.29%
3 Years24.32%
TTM28.59%
Profit CAGR
10 Years-
5 Years3.28%
3 Years45.77%
TTM118.64%
EPS CAGR
10 Years-
5 Years2.34%
3 Years44.12%
TTM120%
Return on Capital
10 Years3.4%
5 Years13.62%
3 Years16.14%
Last Year17.44%
NBIX Recent Earnings
Neurocrine Biosciences, Inc. (NBIX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$1.94+59.0%
$1.22
Rev
$815M+6.0%
$768M
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$1.88+4.4%
$1.80
Rev
$806M+1.9%
$790M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$2.04+29.1%
$1.58
Rev
$795M-1.5%
$807M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$1.06+8.2%
$0.98
Rev
$688M-7.9%
$746M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.94vs $1.22+59.0% | $815Mvs $768M+6.0% |
| Q1 2026 | Feb 11, 2026 | $1.88vs $1.80+4.4% | $806Mvs $790M+1.9% |
| Q4 2025 | Oct 28, 2025 | $2.04vs $1.58+29.1% | $795Mvs $807M-1.5% |
| Q3 2025 | Jul 30, 2025 | $1.06vs $0.98+8.2% | $688Mvs $746M-7.9% |
Based on last 12 quarters of dataView full earnings history →
NBIX Peer Comparison
Neurocrine Biosciences, Inc. (NBIX) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 |
Compare NBIX vs Peers
Neurocrine Biosciences, Inc. (NBIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NBIX Income Statement
Neurocrine Biosciences, Inc. (NBIX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 161.63M | 451.2M | 788.1M | 1.05B | 1.13B | 1.49B | 1.89B | 2.36B | 2.86B | 3.1B |
Revenue Growth % | 977.51% | 179.16% | 74.67% | 32.71% | 8.38% | 31.34% | 26.76% | 24.81% | 21.45% | 28.59% |
Cost of Goods Sold | 1.25M | 4.9M | 7.4M | 10.1M | 14.3M | 23.2M | 39.7M | 34M | 52.1M | 56.7M |
COGS % of Revenue | 0.78% | 1.09% | 0.94% | 0.97% | 1.26% | 1.56% | 2.1% | 1.44% | 1.82% | - |
Gross Profit | 160.37M▲ 0% | 446.3M▲ 178.3% | 780.7M▲ 74.9% | 1.04B▲ 32.7% | 1.12B▲ 8.1% | 1.47B▲ 30.9% | 1.85B▲ 26.1% | 2.32B▲ 25.7% | 2.81B▲ 21.0% | 3.05B▲ 0% |
Gross Margin % | 99.22% | 98.91% | 99.06% | 99.03% | 98.74% | 98.44% | 97.9% | 98.56% | 98.18% | 98.17% |
Gross Profit Growth % | 969.15% | 178.29% | 74.93% | 32.68% | 8.05% | 30.94% | 26.06% | 25.65% | 20.98% | - |
Operating Expenses | 291.73M | 409.5M | 708.4M | 872.8M | 1.02B | 1.22B | 1.6B | 1.75B | 2.19B | 2.26B |
OpEx % of Revenue | 180.5% | 90.76% | 89.89% | 83.45% | 89.7% | 81.72% | 84.6% | 74.33% | 76.54% | - |
Selling, General & Admin | 169.91M | 248.93M | 354.1M | 433.3M | 583.3M | 752.7M | 887.6M | 1.01B | 1.16B | 1.2B |
SG&A % of Revenue | 105.12% | 55.17% | 44.93% | 41.43% | 51.46% | 50.56% | 47.04% | 42.76% | 40.42% | - |
Research & Development | 91.83M | 155.8M | 200M | 275M | 328.1M | 463.8M | 565M | 731.1M | 1.02B | 1.05B |
R&D % of Revenue | 56.81% | 34.53% | 25.38% | 26.29% | 28.95% | 31.15% | 29.94% | 31.04% | 35.51% | - |
Other Operating Expenses | 30M | 4.8M | 154.3M | 164.5M | 105.3M | 0 | 143.9M | 12.5M | 17.4M | 1.3M |
Operating Income | -131.36M▲ 0% | 36.8M▲ 128.0% | 72.3M▲ 96.5% | 163M▲ 125.4% | 102.5M▼ 37.1% | 249M▲ 142.9% | 250.9M▲ 0.8% | 570.5M▲ 127.4% | 619.1M▲ 8.5% | 788.9M▲ 0% |
Operating Margin % | -81.27% | 8.16% | 9.17% | 15.58% | 9.04% | 16.73% | 13.3% | 24.22% | 21.64% | 25.43% |
Operating Income Growth % | 10.86% | 128.01% | 96.47% | 125.45% | -37.12% | 142.93% | 0.76% | 127.38% | 8.52% | - |
EBITDA | -128.96M | 40.82M | 79.75M | 171.6M | 113.4M | 264.6M | 272.2M | 597.6M | 649.2M | 811.4M |
EBITDA Margin % | -79.79% | 9.05% | 10.12% | 16.41% | 10% | 17.77% | 14.42% | 25.37% | 22.7% | 26.15% |
EBITDA Growth % | 11.59% | 131.66% | 95.36% | 115.17% | -33.92% | 133.33% | 2.87% | 119.54% | 8.63% | 55.05% |
D&A (Non-Cash Add-back) | 2.4M | 4.02M | 7.45M | 8.6M | 10.9M | 15.6M | 21.3M | 27.1M | 30.1M | 22.5M |
EBIT | -123.02M | 52.3M | 78.5M | 139.5M | 127.2M | 249M | 394.8M | 612.6M | 636.5M | 665.3M |
Net Interest Income | -19.52M | -30.5M | -32M | -32.8M | -25.8M | 4.1M | -4.6M | -35.6M | 90.3M | 0 |
Interest Income | 0 | 0 | 0 | 0 | 0 | 11.2M | 0 | 91M | 90.3M | 0 |
Interest Expense | 19.52M | 30.53M | 32M | 32.8M | 25.8M | 7.1M | 4.6M | 126.6M | 0 | 0 |
Other Income/Expense | -11.18M | -15.05M | -25.8M | -56.3M | -1.1M | -35.1M | 81.2M | -84.5M | 86.3M | 148.6M |
Pretax Income | -142.54M▲ 0% | 21.84M▲ 115.3% | 46.5M▲ 112.9% | 106.7M▲ 129.5% | 101.4M▼ 5.0% | 213.9M▲ 110.9% | 332.1M▲ 55.3% | 486M▲ 46.3% | 705.4M▲ 45.1% | 937.5M▲ 0% |
Pretax Margin % | -88.19% | 4.84% | 5.9% | 10.2% | 8.95% | 14.37% | 17.6% | 20.63% | 24.66% | 30.22% |
Income Tax | 0 | 730K | 9.5M | -300.6M | 11.8M | 59.4M | 82.4M | 144.7M | 226.8M | 268.9M |
Effective Tax Rate % | 0% | 3.34% | 20.43% | -281.72% | 11.64% | 27.77% | 24.81% | 29.77% | 32.15% | 28.68% |
Net Income | -142.54M▲ 0% | 21.11M▲ 114.8% | 37M▲ 75.3% | 407.3M▲ 1000.8% | 89.6M▼ 78.0% | 154.5M▲ 72.4% | 249.7M▲ 61.6% | 341.3M▲ 36.7% | 478.6M▲ 40.2% | 668.6M▲ 0% |
Net Margin % | -88.19% | 4.68% | 4.69% | 38.94% | 7.9% | 10.38% | 13.23% | 14.49% | 16.73% | 21.55% |
Net Income Growth % | -1.03% | 114.81% | 75.26% | 1000.81% | -78% | 72.43% | 61.62% | 36.68% | 40.23% | 118.64% |
Net Income (Continuing) | -142.54M | 21.11M | 37M | 407.3M | 89.6M | 154.5M | 249.7M | 341.3M | 478.6M | 668.6M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.62▲ 0% | 0.22▲ 113.6% | 0.39▲ 77.3% | 4.16▲ 966.7% | 0.92▼ 77.9% | 1.56▲ 69.6% | 2.47▲ 58.3% | 3.29▲ 33.2% | 4.67▲ 41.9% | 6.47▲ 0% |
EPS Growth % | 0.61% | 113.58% | 77.27% | 966.67% | -77.88% | 69.57% | 58.33% | 33.2% | 41.95% | 120% |
EPS (Basic) | -1.62 | 0.22 | 0.40 | 4.37 | 0.95 | 1.61 | 2.56 | 3.40 | 4.81 | - |
Diluted Shares Outstanding | 88.09M | 95.4M | 95.73M | 97.8M | 97.9M | 98.9M | 101M | 103.7M | 102.5M | 103.4M |
Basic Shares Outstanding | 87.99M | 95.4M | 91.63M | 93.1M | 94.6M | 95.8M | 97.7M | 100.4M | 99.5M | 100.5M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NBIX Balance Sheet
Neurocrine Biosciences, Inc. (NBIX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 554.92M | 737.78M | 831M | 1.02B | 972.8M | 1.45B | 1.61B | 1.72B | 2.52B | 2.44B |
Cash & Short-Term Investments | 515.93M | 650.91M | 670.5M | 801M | 711.3M | 989.3M | 1.03B | 1.08B | 1.48B | 1.32B |
Cash Only | 254.71M | 141.71M | 112.3M | 187.1M | 340.8M | 262.9M | 251.1M | 233M | 713M | 266.5M |
Short-Term Investments | 261.22M | 509.2M | 558.2M | 613.9M | 370.5M | 726.4M | 780.5M | 843.1M | 767.4M | 1.05B |
Accounts Receivable | 31.13M | 57.41M | 126.6M | 157.1M | 185.5M | 350M | 439.3M | 479.1M | 686.8M | 768.1M |
Days Sales Outstanding | 70.29 | 46.44 | 58.63 | 54.83 | 59.73 | 85.81 | 84.97 | 74.25 | 87.64 | 81.73 |
Inventory | 1.02M | 10.86M | 17.3M | 28M | 30.5M | 35.1M | 38.3M | 57.4M | 69M | 64.5M |
Days Inventory Outstanding | 298.05 | 809.26 | 853.31 | 1.01K | 778.5 | 552.22 | 352.13 | 616.21 | 483.4 | 417.95 |
Other Current Assets | 6.84M | 18.59M | 16.6M | 30.1M | 45.5M | 79.1M | 97.8M | 112.1M | 286.5M | 287.3M |
Total Non-Current Assets | 262.67M | 255.37M | 475M | 718.5M | 1.1B | 915.2M | 1.64B | 1.99B | 2.11B | 2.47B |
Property, Plant & Equipment | 10.81M | 33.87M | 116.2M | 127.4M | 155.8M | 145.6M | 347.3M | 592M | 545.2M | 538M |
Fixed Asset Turnover | 14.95x | 13.32x | 6.78x | 8.21x | 7.28x | 10.22x | 5.43x | 3.98x | 5.25x | 5.56x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.7M | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 37.2M | 35.5M | 36.5M | 0 | 0 |
Long-Term Investments | 247.36M | 216.03M | 355.6M | 265.3M | 624.4M | 401.5M | 849.4M | 864.3M | 1.18B | 2.41B |
Other Non-Current Assets | 4.5M | 5.48M | 3.2M | 6.4M | 4.4M | 25M | 49.6M | 9.8M | 59.5M | 1.4B |
Total Assets | 817.59M▲ 0% | 993.15M▲ 21.5% | 1.31B▲ 31.5% | 1.73B▲ 32.8% | 2.07B▲ 19.5% | 2.37B▲ 14.3% | 3.25B▲ 37.3% | 3.72B▲ 14.4% | 4.63B▲ 24.5% | 4.91B▲ 0% |
Asset Turnover | 0.20x | 0.45x | 0.60x | 0.60x | 0.55x | 0.63x | 0.58x | 0.63x | 0.62x | 0.70x |
Asset Growth % | 123.94% | 21.47% | 31.5% | 32.83% | 19.47% | 14.29% | 37.27% | 14.37% | 24.55% | 95.95% |
Total Current Liabilities | 54.43M | 88.23M | 565.3M | 186.5M | 245.8M | 537.7M | 654.8M | 507.7M | 743.4M | 831.7M |
Accounts Payable | 5.65M | 38.38M | 41.4M | 39.4M | 51.5M | 67.3M | 133.3M | 110M | 104.9M | 0 |
Days Payables Outstanding | 1.64K | 2.86K | 2.04K | 1.42K | 1.31K | 1.06K | 1.23K | 1.18K | 734.9 | 530.12 |
Short-Term Debt | 0 | 0 | 408.8M | 0 | 0 | 169.4M | 170.1M | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 25.81M | 42.78M | 84.7M | 90.6M | 133.3M | 225.4M | 261.4M | 297.7M | 423.9M | 831.7M |
Current Ratio | 10.20x | 8.36x | 1.47x | 5.45x | 3.96x | 2.70x | 2.45x | 3.40x | 3.39x | 2.93x |
Quick Ratio | 10.18x | 8.24x | 1.44x | 5.30x | 3.83x | 2.64x | 2.40x | 3.28x | 3.30x | 2.85x |
Cash Conversion Cycle | -1.28K | -2K | -1.13K | -357.16 | -476.28 | -420.78 | -788.46 | -490.43 | -163.87 | -30.45 |
Total Non-Current Liabilities | 391.03M | 424.15M | 103.8M | 422M | 452.7M | 123.2M | 364.6M | 621.3M | 635M | 667.1M |
Long-Term Debt | 369.62M | 388.5M | 0 | 317.9M | 335.1M | 0 | 0 | 0 | 0 | 406.2M |
Capital Lease Obligations | 0 | 0 | 86.7M | 94.4M | 105.3M | 93.5M | 258.3M | 455.1M | 415.3M | 1.28B |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 11.18M | 25.43M | 17.1M | 9.7M | 12.3M | 29.7M | 106.3M | 166.2M | 219.7M | 260.9M |
Total Liabilities | 445.45M | 512.39M | 669.1M | 608.5M | 698.5M | 660.9M | 1.02B | 1.13B | 1.38B | 1.5B |
Total Debt | 369.62M | 388.5M | 495.5M | 412.3M | 440.4M | 262.9M | 428.4M | 455.1M | 415.3M | 406.2M |
Net Debt | 114.91M | 246.78M | 383.2M | 225.2M | 99.6M | 0 | 177.3M | 222.1M | -297.7M | 139.7M |
Debt / Equity | 0.99x | 0.81x | 0.78x | 0.37x | 0.32x | 0.15x | 0.19x | 0.18x | 0.13x | 0.12x |
Debt / EBITDA | - | 9.52x | 6.21x | 2.40x | 3.88x | 0.99x | 1.57x | 0.76x | 0.64x | 0.50x |
Net Debt / EBITDA | - | 6.05x | 4.80x | 1.31x | 0.88x | - | 0.65x | 0.37x | -0.46x | 0.17x |
Interest Coverage | -6.30x | 1.71x | 2.45x | 4.25x | 4.93x | 35.07x | 85.83x | 4.84x | - | - |
Total Equity | 372.14M▲ 0% | 480.76M▲ 29.2% | 636.9M▲ 32.5% | 1.13B▲ 76.8% | 1.37B▲ 22.0% | 1.71B▲ 24.3% | 2.23B▲ 30.7% | 2.59B▲ 16.0% | 3.25B▲ 25.6% | 3.41B▲ 0% |
Equity Growth % | 18.19% | 29.19% | 32.48% | 76.83% | 22% | 24.29% | 30.69% | 16.03% | 25.62% | 77.84% |
Book Value per Share | 4.22 | 5.04 | 6.65 | 11.52 | 14.03 | 17.27 | 22.10 | 24.97 | 31.74 | 32.95 |
Total Shareholders' Equity | 372.14M | 480.76M | 636.9M | 1.13B | 1.37B | 1.71B | 2.23B | 2.59B | 3.25B | 3.41B |
Common Stock | 89K | 91K | 92K | 100K | 100K | 100K | 100K | 100K | 100K | 100K |
Retained Earnings | -1.2B | -1.18B | -1.13B | -725.4M | -635.8M | -406.8M | -157.1M | 29.2M | 447.7M | 589.6M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.85M | -1.93M | 1.4M | 1.8M | -1.7M | -7.9M | 7M | 5.8M | 13.1M | 400K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NBIX Cash Flow Statement
Neurocrine Biosciences, Inc. (NBIX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -94.33M | 101.4M | 147M | 228.5M | 256.5M | 339.4M | 389.9M | 595.4M | 782.7M | 863.7M |
Operating CF Margin % | -58.36% | 22.47% | 18.65% | 21.85% | 22.63% | 22.8% | 20.66% | 25.28% | 27.36% | - |
Operating CF Growth % | 11.16% | 207.49% | 44.97% | 55.44% | 12.25% | 32.32% | 14.88% | 52.71% | 31.46% | 287.05% |
Net Income | -142.54M | 21.1M | 37M | 407.3M | 89.6M | 154.5M | 249.7M | 341.3M | 478.6M | 668.6M |
Depreciation & Amortization | 2.4M | 4M | 7.4M | 8.6M | 10.9M | 15.6M | 21.3M | 27.1M | 30.1M | 29.8M |
Stock-Based Compensation | 42.52M | 58.1M | 75.3M | 100M | 134.2M | 173.1M | 194.3M | 195.5M | 217.9M | 222.3M |
Deferred Taxes | 0 | 0 | 0 | -310.7M | 4.3M | 19.1M | -56.7M | -123.1M | 165.4M | 118M |
Other Non-Cash Items | 12.1M | 19.9M | 32.1M | 61.2M | 800K | 44.5M | -46.9M | 173.8M | 19.5M | -317.9M |
Working Capital Changes | -8.81M | -1.7M | -4.8M | -37.9M | 16.7M | -67.4M | 28.2M | -19.2M | -128.8M | 142.9M |
Change in Receivables | -31.13M | -25.1M | -69.2M | -30.5M | -28.4M | -162.2M | -89.3M | -39.8M | -210.5M | -255M |
Change in Inventory | -1.02M | -3.5M | -6.4M | -10.7M | -2.5M | -2.6M | 5.4M | -19.1M | -15.3M | -9.3M |
Change in Payables | 27.34M | 0 | 0 | 26.9M | 56.8M | 114.6M | 64.3M | 29M | 160.2M | 133.5M |
Cash from Investing | -251.25M | -242.9M | -211.1M | 4.1M | -130.2M | -177.1M | -467.1M | -126.8M | -264.4M | -784.8M |
Capital Expenditures | -6.94M | -24.8M | -14.7M | -10.9M | -23.4M | -16.5M | -28.3M | -38.2M | -34M | -32.4M |
CapEx % of Revenue | 4.29% | 5.5% | 1.87% | 1.04% | 2.06% | 1.11% | 1.5% | 1.62% | 1.19% | 1.04% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -42.7M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 7K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 63.2M |
Cash from Financing | 516.65M | 29.5M | 32.4M | -157.8M | 27.4M | -234.3M | 65.3M | -486.7M | -38.3M | -6.5M |
Debt Issued (Net) | 502.78M | 0 | 0 | -186.9M | -100K | -279M | 0 | -308.8M | 0 | 0 |
Equity Issued (Net) | 13.87M | 29.53M | 27.31M | 29.1M | 27.5M | 44.7M | 65.3M | -177.9M | -38.3M | 79.6M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -300M | -167.7M | -71.7M |
Other Financing | 0 | -30K | 5.09M | 0 | 0 | 0 | 0 | 0 | 0 | -86.1M |
Net Change in Cash | 171.06M▲ 0% | -112M▼ 165.5% | -31.7M▲ 71.7% | 74.8M▲ 336.0% | 153.7M▲ 105.5% | -73.3M▼ 147.7% | -11.6M▲ 84.2% | -18.1M▼ 56.0% | 480M▲ 2751.9% | 72.4M▲ 0% |
Free Cash Flow | -101.27M▲ 0% | 76.6M▲ 175.6% | 132.3M▲ 72.7% | 217.6M▲ 64.5% | 233.1M▲ 7.1% | 322.9M▲ 38.5% | 361.6M▲ 12.0% | 557.2M▲ 54.1% | 748.7M▲ 34.4% | 831.3M▲ 0% |
FCF Margin % | -62.66% | 16.98% | 16.79% | 20.8% | 20.56% | 21.69% | 19.16% | 23.66% | 26.17% | 26.8% |
FCF Growth % | 8.18% | 175.64% | 72.72% | 64.47% | 7.12% | 38.52% | 11.99% | 54.09% | 34.37% | 68.89% |
FCF per Share | -1.15 | 0.80 | 1.38 | 2.22 | 2.38 | 3.26 | 3.58 | 5.37 | 7.30 | 8.04 |
FCF Conversion (FCF/Net Income) | 0.66x | 4.80x | 3.97x | 0.56x | 2.86x | 2.20x | 1.56x | 1.74x | 1.64x | 1.24x |
Interest Paid | 0 | 0 | 11.6M | 11.6M | 8.6M | 6.6M | 3.8M | 1.6M | 0 | 0 |
Taxes Paid | 0 | 0 | 500K | 15.3M | 5.1M | 14.4M | 51.5M | 217.5M | 81.4M | 80.8M |
NBIX Key Ratios
Neurocrine Biosciences, Inc. (NBIX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -41.5% | 4.95% | 6.62% | 46.2% | 7.17% | 10.03% | 12.68% | 14.16% | 16.38% | 21.64% |
Return on Invested Capital (ROIC) | -27.42% | 4.54% | 6.21% | 10.31% | 5.44% | 11.74% | 9.14% | 16.39% | 16.1% | 18.28% |
Gross Margin | 99.22% | 98.91% | 99.06% | 99.03% | 98.74% | 98.44% | 97.9% | 98.56% | 98.18% | 98.17% |
Net Margin | -88.19% | 4.68% | 4.69% | 38.94% | 7.9% | 10.38% | 13.23% | 14.49% | 16.73% | 21.55% |
Debt / Equity | 0.99x | 0.81x | 0.78x | 0.37x | 0.32x | 0.15x | 0.19x | 0.18x | 0.13x | 0.12x |
Interest Coverage | -6.30x | 1.71x | 2.45x | 4.25x | 4.93x | 35.07x | 85.83x | 4.84x | - | - |
FCF Conversion | 0.66x | 4.80x | 3.97x | 0.56x | 2.86x | 2.20x | 1.56x | 1.74x | 1.64x | 1.24x |
Revenue Growth | 977.51% | 179.16% | 74.67% | 32.71% | 8.38% | 31.34% | 26.76% | 24.81% | 21.45% | 28.59% |
Related:NBIX Dividend History·NBIX Revenue History·NBIX Price History·NBIX P/E History·NBIX Financial Ratios·NBIX Institutional Holders
NBIX SEC Filings & Documents
Neurocrine Biosciences, Inc. (NBIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
NBIX Frequently Asked Questions
Neurocrine Biosciences, Inc. (NBIX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Neurocrine Biosciences, Inc. (NBIX) reported $3.10B in revenue for fiscal year 2025. This represents a 16058% increase from $19.2M in 1996.
Neurocrine Biosciences, Inc. (NBIX) grew revenue by 21.4% over the past year. This is strong growth.
Yes, Neurocrine Biosciences, Inc. (NBIX) is profitable, generating $668.6M in net income for fiscal year 2025 (16.7% net margin).
Dividend & Returns
Neurocrine Biosciences, Inc. (NBIX) has a return on equity (ROE) of 16.4%. This is reasonable for most industries.
Neurocrine Biosciences, Inc. (NBIX) generated $831.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.